Contenu connexe Plus de Renub Research (16) Global diabetes market trends & future forecast – diabetes drug (anti diabetic drug), insulin, dpp-iv, glp-12. © Renub Research Page 2 of 10
Report Details
“Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug),
Insulin, DPP-IV, GLP-1” report published by Renub Research provides an in-depth analysis of
the past, present and future prospects. The report has been researched at source globally,
country specific and features latest available data covering:
Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
Region wise Diabetes Health Expenditure and Mortality
Top 10 Countries Diabetes Population and Future Forecast
Top 5 Countries Diabetes Drug Market and Future Forecast
Top 7 Countries Insulin Market and Future Forecast
Top 6 Diabetes Drug Brands (Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm,
Starlix) data of Past, Present and Future Market
Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog,
Humulin, Apidra, Lantus) data of Past, Present and Future Market
Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past,
Present and Future Market
Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of
Past, Present and Future Market
Research Highlights
USA controls more than 50% of the total Diabetes Drug market share in 2009
Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
China will have the second highest Insulin market share by 2012 replacing Germany
DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3
Billion by 2015.
3. © Renub Research Page 3 of 10
Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and
cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more
than US$ 4 Billion by 2017
Last year launched Victoza and yet to be launched Exenatide LAR is going to be
blockbuster GLP-1 Agonists
China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
Japan Insulin market is expected to be more than US$ 1 Billion by 2010
Key Drugs Analyzed
Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix
Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra,
Lantus
DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus,
GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide
Data Sources
Information and data in this report has been collected from various printable and non-
printable sources like Trade Journals, White papers, Online paid databases, News websites,
Government Agencies, Magazines, Newspapers and Trade associations.
4. © Renub Research Page 4 of 10
Table of Contents
1. Executive Summary
2. Global Diabetes Market
2.1 Global – Diabetes Drug Market & Future Forecast
2.2 Global – Insulin Market & Future Forecast
2.3 Global – Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India)
2.4 Global – Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan,
USA, India)
2.5 Global – Dipeptidyl Peptidase (DPP – IV) Inhibitors Market & Future Forecast
2.6 Global – Glucagon-like Peptide-1(GLP-1) Market & Future Forecast
3. Global – Top 6 Diabetes Drug Brands Market Performance
3.1 Avandia – Past & Present Market
3.2 Actos – Past, Present & Future Forecast
3.3 Amaryl – Past, Present & Future Forecast
3.4 Avandamet – Past, Present & Future Forecast
3.5 Prandin/Novonorm – Past & Present Market
3.6 Starlix – Past, Present & Future Forecast
4. Global – Top 9 Insulin Brands Market Performance
4.1 Novomix – Past, Present & Future Forecast
4.2 Novorapid – Past, Present & Future Forecast
4.3 Levemir – Past, Present & Future Forecast
4.4 Degludec – Yet to be Launched - Future Forecast
4.5 Degludecplus – Yet to be Launched – Future Forecast
4.6 Humalog – Past & Present Market
4.7 Humulin – Past & Present Market
4.8 Apidra – Past, Present & Future Forecast
4.9 Lantus – Past, Present & Future Forecast
5. © Renub Research Page 5 of 10
5. Global – DPP-IV Inhibitors Brands Market Performance
5.1 Januvia – Past, Present & Future Forecast
5.2 Onglyza – Past, Present & Future Forecast
5.3 Alogliptin – Yet to be Launched – Future Forecast
5.4 Galvus – Past, Present & Future Forecast
5.5 DPP-IV Inhibitors – In Trial Phases
6. Global – GLP-1 Agonists Brands Market Performance
6.1 Byetta – Past, Present & Future Forecast
6.2 Victoza – Past, Present & Future Forecast
6.3 Exenatide LAR – Yet to be Launched – Future Forecast
6.4 Syncria – Yet to be Launched – Future Forecast
6.5 Taspoglutide – Yet to be Launched – Future Forecast
7. Regional Estimates for Diabetes
7.1 Diabetes – Population & Prevalence
7.2 Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.3 Mortality – Due to Diabetes
7.4 North America & Caribbean Region
7.4.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.4.2 Healthcare Expenditure & Type 1 Diabetes
7.4.3 Mortality
7.5 Middle East and North African Region
7.5.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.5.2 Healthcare Expenditure & Type 1 Diabetes
7.5.3 Mortality
7.6 South-East Asian Region
7.6.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.6.2 Healthcare Expenditure & Type 1 Diabetes
7.6.3 Mortality
7.7 European Region
7.7.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.7.2 Healthcare Expenditures & Type 1 Diabetes
6. © Renub Research Page 6 of 10
7.7.3 Mortality
7.8 South and Central American Region
7.8.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.8.2 Healthcare Expenditures & Type 1 Diabetes
7.8.3 Mortality
7.9 Western Pacific Region
7.9.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.9.2 Healthcare Expenditures & Type 1 Diabetes
7.9.3 Mortality
7.10 African Region
7.10.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
7.10.2 Healthcare Expenditure & Type 1 Diabetes
7.10.3 Mortality
8. Global – Top 10 Diabetic Countries Performance
8.1 Number of People in Top 10 Diabetic Place
8.2 Prevalence of Diabetes in Top 10 Countries
8.3 India
8.3.1 Diabetes Population & Future Scenario
8.3.2 India – Diabetes Drug Market & Future Forecast
8.3.3 India-Insulin Market & Future Forecast
8.4 China
8.4.1 Diabetes Population & Future Scenario
8.4.2 Diabetes Drug Market & Future Forecast
8.4.3 China Insulin Market & Future Forecast
8.5 United States
8.5.1 Diabetes Population & Future Scenario
8.5.2 Diabetes Drug Market & Future Forecast
8.5.3 Insulin Market & Future Forecast
8.6 Brazil
8.6.1 Diabetes Population & Future Scenario
8.6.2 Diabetes Drug Market & Future Forecast
8.7 Russia
8.7.1 Diabetes Population & Future Scenario
8.7.2 Insulin Market & Future Forecast
7. © Renub Research Page 7 of 10
8.8 Japan
8.8.1 Diabetes Population & Future Scenario
8.8.2 Diabetes Drug Market & Future Forecast
8.8.3 Insulin Market & Future Forecast
8.9 Germany
8.9.1 Diabetes Population & Future Scenario
8.9.2 Insulin Market & Future Forecast
8.10 Mexico
8.10.1 Diabetes Population & Future Scenario
8.10.2 Insulin Market & Future Forecast
8.11 Indonesia
8.11.1 Diabetes Population & Future Scenario
8.12 Pakistan
8.12.1 Diabetes Population & Future Scenario
8. © Renub Research Page 8 of 10
Order Form
Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact
Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780
Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to
info@renub.com
Format
Report Title: Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic
Drug), Insulin, DPP-IV, GLP-1
Single User
(Email from Publisher)
Hard Copy
(Mail Delivery)
CD – Rom
(Mail Delivery)
Global Site License
(Multiple User License)
US$ 1,100 US$ 1,250 US$ 1,250 US$ 1,600
For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.):
http://www.renub.com/report/global-diabetes-market-trends-future-forecast---diabetes-
drug-anti-diabetic-drug-insulin-dpp-iv-glp-1-27
2) Order by Wire Transfer:
http://www.renub.com/report/wiretransfer.aspx?id=27&pid=1092
To pay by Wire Transfer, please, fill in your contact details in the form below:
9. © Renub Research Page 9 of 10
Bank Details
Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th
Floor
Indian Red Cross Building
1 Red Cross Road
Opposite Parliament Street
New Delhi – 110001
India
Contact Information
First Name: Last Name:
Email:
Job Title:
Company:
Address:
City:
Postal/Zip Code:
Country:
Phone:
Mobile:
Fax:
Report Format:
Your message:
10. © Renub Research Page 10 of 10
3) Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research
1st
Floor
C-86, Sector -10
Noida - 201301
Uttar Pradesh
India
Phone: +91-120-4219-822, 4249-780
For free Sample copy report or to view any of our sample work please contact us at
info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)
Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090
LinkedIn: http://www.linkedin.com/company/renub-research
Twitter: http://twitter.com/RenubResearch